Literature DB >> 19121577

Stat3 activation is required for the growth of U87 cell-derived tumours in mice.

Atreyi Dasgupta1, Baisakhi Raychaudhuri, Talat Haqqi, Richard Prayson, Erwin G Van Meir, Michael Vogelbaum, Saikh Jaharul Haque.   

Abstract

Previously we reported that Stat3 is persistently activated in GBM tumours and derived cell lines. Hypoxia, necrosis and neo-angiogenesis are hallmarks of GBM. To unfold the contribution of activated Stat3 to the growth of GBM, we generated human GBM cell line (U87)-derived stable clones expressing a dominant negative mutant (DN)-Stat3 in a hypoxia-inducible manner, and examined their tumour-forming potentials in immune-compromised mice. We found that the parental and vector control cell-derived tumours grew steadily, whereas DN-Stat3-expressing clone-derived tumours failed to grow beyond 2mm of thickness in mouse flanks. This blockade of tumour growth was associated with induction of tumour cell apoptosis and suppression of tumour angiogenesis. Consistent with this, mice bearing orthotopically implanted DN-Stat3-expressing clones survived significantly longer than the control mice. These data suggest that activated Stat3 is required for the growth of GBM, and that targeting Stat3 may intervene with the growth of GBM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19121577      PMCID: PMC5424891          DOI: 10.1016/j.ejca.2008.11.027

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  34 in total

Review 1.  Malignant glioma: genetics and biology of a grave matter.

Authors:  E A Maher; F B Furnari; R M Bachoo; D H Rowitch; D N Louis; W K Cavenee; R A DePinho
Journal:  Genes Dev       Date:  2001-06-01       Impact factor: 11.361

Review 2.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 3.  Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.

Authors:  Daniel J Brat; Amilcar Castellano-Sanchez; Balveen Kaur; Erwin G Van Meir
Journal:  Adv Anat Pathol       Date:  2002-01       Impact factor: 3.875

4.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.

Authors:  K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.

Authors:  Shaik Ohidar Rahaman; Michael A Vogelbaum; S Jaharul Haque
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

6.  Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling.

Authors:  S J Haque; P C Harbor; B R Williams
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

7.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

8.  Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity.

Authors:  Suzy A A Comhair; Weiling Xu; Sudakshina Ghosh; Frederik B J M Thunnissen; Alexandru Almasan; William J Calhoun; Allison J Janocha; Lemin Zheng; Stanley L Hazen; Serpil C Erzurum
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 9.  CD105 is important for angiogenesis: evidence and potential applications.

Authors:  Sarah E Duff; Chenggang Li; John M Garland; Shant Kumar
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

10.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

View more
  25 in total

1.  STAT3 tyrosine phosphorylation influences survival in glioblastoma.

Authors:  Peter Birner; Kalina Toumangelova-Uzeir; Sevdalin Natchev; Marin Guentchev
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

Review 2.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

3.  Sorafenib exerts anti-glioma activity in vitro and in vivo.

Authors:  Markus D Siegelin; Christopher M Raskett; Candace A Gilbert; Alonzo H Ross; Dario C Altieri
Journal:  Neurosci Lett       Date:  2010-05-12       Impact factor: 3.046

4.  Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter.

Authors:  Mi-Kyung Oh; Hyo-Jung Park; Nam-Hoon Kim; Seon-Joo Park; In-Yang Park; In-Sook Kim
Journal:  J Biol Chem       Date:  2011-01-11       Impact factor: 5.157

5.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Authors:  Olga A Guryanova; Qiulian Wu; Lin Cheng; Justin D Lathia; Zhi Huang; Jinbo Yang; Jennifer MacSwords; Christine E Eyler; Roger E McLendon; John M Heddleston; Weinian Shou; Dolores Hambardzumyan; Jeongwu Lee; Anita B Hjelmeland; Andrew E Sloan; Markus Bredel; George R Stark; Jeremy N Rich; Shideng Bao
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

Review 6.  NF-kappaB and STAT3 signaling in glioma: targets for future therapies.

Authors:  George P Atkinson; Susan E Nozell; Etty Tika N Benveniste
Journal:  Expert Rev Neurother       Date:  2010-04       Impact factor: 4.618

7.  Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.

Authors:  Ke Sai; Shuzhen Wang; Veerakumar Balasubramaniyan; Charles Conrad; Frederick F Lang; Kenneth Aldape; Slawomir Szymanski; Izabela Fokt; Atreyi Dasgupta; Timothy Madden; Su Guan; Zhongping Chen; W K Alfred Yung; Waldemar Priebe; Howard Colman
Journal:  J Neurooncol       Date:  2012-01-17       Impact factor: 4.130

Review 8.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma.

Authors:  Guo-Shi Lin; Li-Juan Yang; Xing-Fu Wang; Yu-Peng Chen; Wen-Long Tang; Long Chen; Zhi-Xiong Lin
Journal:  Med Oncol       Date:  2014-03-21       Impact factor: 3.064

10.  MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway.

Authors:  Li Hong; Liu Ya-Wei; Wang Hai; Zhou Qiang; Li Jun-Jie; Annie Huang; Qi Song-Tao; Lu Yun-Tao
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.